PPARG and early-onset autosomal dominant Alzheimer disease: Rosiglitazone (RSG) is a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist of the thiazolidinedione (TZD) class used to treat type 2 diabetes mellitus (T2DM) and potentially Alzheimer’s disease (AD) [1,2,3,4,5].